机构:[1]Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan.[2]Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.[3]UCL Institute of Ophthalmology, London, United Kingdom.[4]Division of Public Health, Yokokawa Clinic, Suita, Japan.[5]Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.[6]Southwest Hospital, Army Medical University, Chongqing, China.[7]Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing, China.[8]Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.[9]Department of Ophthalmology, Mie University Graduate School of Medicine, Mie, Japan.[10]Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.[11]Moorfields Eye Hospital, London, United Kingdom.[12]Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan.[13]Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.[14]Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.[15]Endowed Course for Health System Innovation, Keio University School of Medicine, Tokyo, Japan.
To characterize the clinical effects of two RP1L1 hotspots in patients with East Asian occult macular dystrophy (OMD).Fifty-one patients diagnosed with OMD harboring monoallelic pathogenic RP1L1 variants (Miyake disease) from Japan, South Korea, and China were enrolled. Patients were classified into two genotype groups: group A, p.R45W, and group B, missense variants located between amino acids (aa) 1196 and 1201. The clinical parameters of the two genotypes were compared, and deep learning based on spectral-domain optical coherence tomographic (SD-OCT) images was used to distinguish the morphologic differences.Groups A and B included 29 and 22 patients, respectively. The median age of onset in groups A and B was 14.0 and 40.0 years, respectively. The median logMAR visual acuity of groups A and B was 0.70 and 0.51, respectively, and the survival curve analysis revealed a 15-year difference in vision loss (logMAR 0.22). A statistically significant difference was observed in the visual field classification, but no significant difference was found in the multifocal electroretinographic classification. High accuracy (75.4%) was achieved in classifying genotype groups based on SD-OCT images using machine learning.Distinct clinical severities and morphologic phenotypes supported by artificial intelligence-based classification were derived from the two investigated RP1L1 hotspots: a more severe phenotype (p.R45W) and a milder phenotype (1196-1201 aa). This newly identified genotype-phenotype association will be valuable for medical care and the design of therapeutic trials.
基金:
Supported by grants from Grant-in-Aid for Young Scientists of
the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943) (YF-Y); JSPS KAKENHI Grant Numbers
21J21086, 22KJ2665 (Research Fellowships for Young Scientists [DC1], Japan) (YF-Y); Japan Agency for Medical Research
and Development (AMED), the Ministry of Health, Labor and
Welfare, Japan (18ek0109282h0002), Grants-in-Aid for Scientific
Research, and Japan Society for the Promotion of Science, Japan
(H26-26462674) (KT); National Institute for Health Research
Biomedical Research Centre at Moorfields Eye Hospital NHS
Foundation Trust and UCL Institute of Ophthalmology (AGR);
a Fight for Sight (UK) Early Career Investigator Award, NIHRBRC at Moorfields Eye Hospital and the UCL Institute of
Ophthalmology, and Great Britain Sasakawa Foundation Butterfield Award, UK (GA); grants from Foundation Fighting Blindness (CD-CL-0214-0631-PUMCH), CAMS Innovation Fund for
Medical Sciences (CIFMS 2016-12M-1-002), and National Natural Science Foundation of China (81470669) (RS); a research
grant from the Seoul National University Bundang Hospital
(02-2017-059) and the National Research Foundation of Korea
Grant 2016R1D1A1B03934724, funded by the Korean government (Ministry of Science, ICT and Future Planning) (SJW);
grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, and The
Wellcome Trust (099173/Z/12/Z) (MM); and a Grant-in-Aid for
Young Scientists (A) of the Ministry of Education, Culture,
Sports, Science and Technology, Japan (16H06269), grants from
a Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science
and Technology, Japan (16KK01930002), grants from National
Hospital Organization Network Research Fund, Japan (H30-
NHO-Sensory Organs-03), grants from the Foundation Fighting Blindness Alan Laties Career Development Program (CF-CL-
0416-0696-UCL), grants from Health Labour Sciences Research
Grant, AMED (23EK0109634H0001, 23EK0109632H0001), The
Ministry of Health Labour and Welfare, Japan (201711107A,
23809955, 23FC1056), grants from Great Britain Sasakawa Foundation Butterfield Awards, UK, and grant from National Institute of Health and Care Research (AI AWARD 02488) (KF).
Laboratory of Visual Physiology, Division for Vision Research,
National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan, is supported
by grants from Astellas Pharma Inc (NCT03281005), Jansen
Pharma (NCT04868916), and National Institute for Health
and Care Research (NIHR), outside the submitted work
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|2 区眼科学
最新[2023]版:
大类|2 区医学
小类|2 区眼科学
第一作者:
第一作者机构:[1]Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan.[2]Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.[3]UCL Institute of Ophthalmology, London, United Kingdom.[4]Division of Public Health, Yokokawa Clinic, Suita, Japan.
通讯作者:
通讯机构:[2]Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.[3]UCL Institute of Ophthalmology, London, United Kingdom.[11]Moorfields Eye Hospital, London, United Kingdom.[*1]Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan
推荐引用方式(GB/T 7714):
Fujinami-Yokokawa Yu,Joo Kwangsic,Liu Xiao,et al.Distinct Clinical Effects of Two RP1L1 Hotspots in East Asian Patients With Occult Macular Dystrophy (Miyake Disease): EAOMD Report 4[J].Investigative Ophthalmology & Visual Science.2024,65(1):41.doi:10.1167/iovs.65.1.41.
APA:
Fujinami-Yokokawa Yu,Joo Kwangsic,Liu Xiao,Tsunoda Kazushige,Kondo Mineo...&Fujinami Kaoru.(2024).Distinct Clinical Effects of Two RP1L1 Hotspots in East Asian Patients With Occult Macular Dystrophy (Miyake Disease): EAOMD Report 4.Investigative Ophthalmology & Visual Science,65,(1)
MLA:
Fujinami-Yokokawa Yu,et al."Distinct Clinical Effects of Two RP1L1 Hotspots in East Asian Patients With Occult Macular Dystrophy (Miyake Disease): EAOMD Report 4".Investigative Ophthalmology & Visual Science 65..1(2024):41